All NewsFDA BriefsOncology IconsSpecial ReportsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision MedicineSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD: Case 1

home / case-based-peer-perspectives / relapse-refractory-cll-case1

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Javier Pinilla-Ibarz, MD, PhD: Principle Treatment Options for Patients With a 17p Deletion

EP. 1: Javier Pinilla-Ibarz, MD, PhD: Principle Treatment Options for Patients With a 17p Deletion

September 25th 2015

Watch

Javier Pinilla-Ibarz, MD, PhD: Additional Chemo-Immunotherapy

EP. 2: Javier Pinilla-Ibarz, MD, PhD: Additional Chemo-Immunotherapy

September 25th 2015

Watch

Javier Pinilla-Ibarz, MD, PhD: Use of Bruton's Tyrosine Kinase Inhibitor

EP. 3: Javier Pinilla-Ibarz, MD, PhD: Use of Bruton's Tyrosine Kinase Inhibitor

September 25th 2015

Watch

Javier Pinilla-Ibarz, MD, PhD: Dose Intensity

EP. 4: Javier Pinilla-Ibarz, MD, PhD: Dose Intensity

September 25th 2015

Watch

Javier Pinilla-Ibarz, MD, PhD: Significance of Treating to Progression

EP. 5: Javier Pinilla-Ibarz, MD, PhD: Significance of Treating to Progression

September 25th 2015

Watch

Paul Barr, MD: Principle Treatment Options for Patients With a 17p Deletion

EP. 6: Paul Barr, MD: Principle Treatment Options for Patients With a 17p Deletion

September 25th 2015

Watch

Paul Barr, MD: Additional Chemo-Immunotherapy

EP. 7: Paul Barr, MD: Additional Chemo-Immunotherapy

September 25th 2015

Watch

Paul Barr, MD: Dose Intensity

EP. 8: Paul Barr, MD: Dose Intensity

September 25th 2015

Watch

Paul Barr, MD: Significance of Treating to Progression

EP. 9: Paul Barr, MD: Significance of Treating to Progression

September 25th 2015

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.